240 related articles for article (PubMed ID: 29221663)
1. [Long-term outcomes of prostate cancer patients with lymph nodes metastasis after radical prostatectomy and pelvic lymph node dissection].
De Vergie S; Gaschignard N; Baron M; Branchereau J; Luyckx F; Butel T; Perrouin-Verbe MA; Bouchot O; Rigaud J
Prog Urol; 2018 Jan; 28(1):25-31. PubMed ID: 29221663
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
3. [When to introduce hormone therapy after total prostatectomy with positive lymph nodes? Study of the factors influencing the time of introduction of hormone therapy].
Duquesne I; Champy C; Klap J; Chahwan C; Vordos D; de la Taille A; Salomon L
Prog Urol; 2019 Dec; 29(16):981-988. PubMed ID: 31735682
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of patients with lymph node-positive prostate cancer following radical prostatectomy and extended sentinel lymph node dissection.
Muck A; Langesberg C; Mugler M; Rahnenführer J; Wullich B; Schafhauser W
Urol Int; 2015; 94(3):296-306. PubMed ID: 25170747
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
6. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
[TBL] [Abstract][Full Text] [Related]
7. Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.
Mandel P; Rosenbaum C; Pompe RS; Steuber T; Salomon G; Chun FK; Graefen M; Huland H; Tilki D
World J Urol; 2017 Dec; 35(12):1833-1839. PubMed ID: 28828530
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
9. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
Preisser F; van den Bergh RCN; Gandaglia G; Ost P; Surcel CI; Sooriakumaran P; Montorsi F; Graefen M; van der Poel H; de la Taille A; Briganti A; Salomon L; Ploussard G; Tilki D;
J Urol; 2020 Feb; 203(2):338-343. PubMed ID: 31437119
[TBL] [Abstract][Full Text] [Related]
10. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection.
Passoni NM; Abdollah F; Suardi N; Gallina A; Bianchi M; Tutolo M; Fossati N; Gandaglia G; Salonia A; Freschi M; Rigatti P; Montorsi F; Briganti A
Urol Oncol; 2014 Jan; 32(1):29.e21-8. PubMed ID: 23490908
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
13. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
Marra G; Valerio M; Heidegger I; Tsaur I; Mathieu R; Ceci F; Ploussard G; van den Bergh RCN; Kretschmer A; Thibault C; Ost P; Tilki D; Kasivisvanathan V; Moschini M; Sanchez-Salas R; Gontero P; Karnes RJ; Montorsi F; Gandaglia G;
Eur Urol Oncol; 2020 Oct; 3(5):565-581. PubMed ID: 32933887
[TBL] [Abstract][Full Text] [Related]
14. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.
Briganti A; Karnes JR; Da Pozzo LF; Cozzarini C; Gallina A; Suardi N; Bianchi M; Freschi M; Doglioni C; Fazio F; Rigatti P; Montorsi F; Blute ML
Eur Urol; 2009 Feb; 55(2):261-70. PubMed ID: 18838212
[TBL] [Abstract][Full Text] [Related]
15. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.
Yaxley JW; Dagher J; Delahunt B; Egevad L; Srigley J; Samaratunga H
World J Urol; 2018 Jan; 36(1):15-20. PubMed ID: 29116393
[TBL] [Abstract][Full Text] [Related]
16. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.
von Bodman C; Godoy G; Chade DC; Cronin A; Tafe LJ; Fine SW; Laudone V; Scardino PT; Eastham JA
J Urol; 2010 Jul; 184(1):143-8. PubMed ID: 20478587
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
19. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
[TBL] [Abstract][Full Text] [Related]
20. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes.
Ledezma RA; Negron E; Razmaria AA; Dangle P; Eggener SE; Shalhav AL; Zagaja GP
World J Urol; 2015 Nov; 33(11):1689-94. PubMed ID: 25701128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
